FIELD: pharmaceuticals.
SUBSTANCE: present invention refers to a composition containing (a) botulinum toxin and (b) non-crosslinked hyaluronic acid, and its application for treating or preventing dystonia, spastic condition and/or wrinkles. Besides, the present invention refers to a method for cosmetic smoothing or wrinkle prevention, which involves the stage of introduction of the present composition. Described is a composition for preventing or treating a disease or condition which can be prevented or cured by botulinum neurotoxin A, comprising a) 2–4 or 20–40 units of botulinum neurotoxin A per milligram of non-crosslinked hyaluronic acid, b) 2.5–9 mg of non-crosslinked hyaluronic acid having average molecular weight from 2.5 to 4.5 MDA, where the disease or condition is selected from focal, segmental or generalized dystonia, spastic condition or wrinkles, and where the polydispersity index of the non-crosslinked hyaluronic acid ranges from 1.1 to 4.0.
EFFECT: technical result is creation of improved composition with botulinum neurotoxin, providing prolonged action of botulinum toxin, prevention or at least considerable reduction of undesirable by-effects.
12 cl, 1 ex, 2 dwg
Title |
Year |
Author |
Number |
LIQUID COMPOSITION OF NEUROTOXIN STABILIZED WITH TRYPTOPHAN OR TYROSINE |
2017 |
- Yarstad, Anders
- Friis, Anna
- Shtal, Ulf
- Gurell, Ann
- Agren, Barbro
- Edstrom, Emiliya
- Pikett, Endryu
|
RU2741497C2 |
CLOSTRIDIAL NEUROTOXINS WITH MODIFIED PERSISTENCE |
2009 |
|
RU2524429C2 |
PHARMACEUTICAL COMPOSITION FOR TREATING PAIN SYNDROME IN FOOT, COMPRISING BOTULINUM TOXIN AND HYALURONIC ACID, AND METHOD OF TREATING PAIN SYNDROME IN FOOT WITH USE THEREOF |
2018 |
- Jang, Sung Su
- Lee, Haksup
- Ahn, Yongshik
- Kim, Jonghyo
- Shin, Seungjin
|
RU2734159C1 |
PROLONGED-RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING POLOXAMER |
2009 |
|
RU2482874C2 |
HIGH INTRODUCTION RATE OF NEUROTOXIC COMPONENT OF BOTULINUM TOXIN |
2007 |
- Marks Mattias
- Grafe Zuzanne
- Benekke Rajner
- Dressler Dirk
|
RU2453333C2 |
LIQUID PHARMACEUTICAL COMPOSITION OF BOTULINUM TOXIN |
2008 |
- Dzjung Khun Kho
- Jang Gi Khueok
- Kim Khak Voo
- Voo Khee Dong
- Rkhee Chang Khoon
|
RU2440825C2 |
SIMULTANEOUS, SEPARATE OR SEPARATED IN TIME THERAPEUTIC APPLICATION OF, AT LEAST, ONE BOTULIC NEUROTOXIN AND, AT LEAST, ONE OPIATE DERIVATIVE |
2007 |
- Oge Mishel'
- Favr Kristin
- Shabrie De Lasson'Er P'Er-Eht'Enn
|
RU2434637C2 |
METHOD FOR BOTULINUM TOXIN PRODUCTION |
2014 |
- Kim Chon Sej
- Son Kvan En
- Min Ken Min
- An En Tuk
|
RU2627159C2 |
PEG-YLATED MUTANT TOXIN CLOSTRIDIUM BOTULINUM |
2007 |
- Frefert Jurgen
- Shpekht Fol'Ker
|
RU2426739C2 |
COMPOSITIONS AND METHODS FOR IMPROVING DRUG THERAPY WITH METAL ION DEPENDANT AGENTS |
2010 |
|
RU2540520C2 |